pharma · Acute Ischemic Stroke · Chronic Kidney Disease · DMAC
DiaMedica Therapeutics
DiaMedica Therapeutics is a pharma organization headquartered in Minneapolis, USA. It trades on NYSE under ticker DMAC. Primary therapeutic focus areas include Acute Ischemic Stroke, Chronic Kidney Disease, Diabetes Type
Minneapolis, USA HQ
45 Employees
Public company Type
DMAC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Minneapolis, USA
- Employees
- 45
- Programs
- 8
- Drugs
- 7
- Patents
- 9
DM199
Phase 1 · small molecule · Chronic Kidney Disease
DM199 for Chronic Kidney Disease is a Phase 1 program (small_molecule) at DiaMedica Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code DM199-2018-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- DiaMedica Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Chronic Kidney Disease
- Status
- completed
- Trials
- 1